PMID- 1985870
OWN - NLM
STAT- MEDLINE
DCOM- 19910212
LR  - 20190708
IS  - 0020-7136 (Print)
IS  - 0020-7136 (Linking)
VI  - 47
IP  - 1
DP  - 1991 Jan 2
TI  - Anti-tumor effects of recombinant human macrophage colony-stimulating factor, 
      alone or in combination with local irradiation, in mice inoculated with Lewis 
      lung carcinoma cells.
PG  - 143-7
AB  - Recombinant human (rhu) macrophage colony-stimulating factor (M-CSF) was 
      evaluated for efficacy, either alone or in combination with local X-irradiation 
      (LR), in mice inoculated subcutaneously (s.c.) with Lewis lung carcinoma (LLC) 
      cells. The size of the primary tumor and numbers of lung metastases, 21 days 
      after tumor inoculation and 15 days after the start of treatment, were reduced by 
      87% in tumor-bearing mice treated with 20 micrograms/dose M-CSF s.c. twice a day 
      for 5 days. LR (800 cGy) to the tumor once a week for 2 weeks had a moderate 
      anti-tumor effect and enhanced the anti-tumor effect of M-CSF. Hematological 
      parameters, including nucleated cellularity in peripheral blood, femoral marrow, 
      spleen and peritoneal exudate, as well as marrow and splenic 
      granulocyte-macrophage progenitor cells, and numbers of splenic Thy 1.2+ cell and 
      peritoneal mast cells, were perturbed in LLC-bearing mice, and were influenced by 
      treatment with M-CSF and LR. Treatment with M-CSF plus LR, but not with either 
      agent alone, was associated with a significant, although slight, enhancement in 
      survival time for LLC-bearing mice. Inability to obtain a better 
      survival-enhancing effect appeared to be related to the limited treatment, since 
      the anti-tumor effects of M-CSF were more notable early on in disease progression 
      and were related to the dose of M-CSF used. The effects of M-CSF were most 
      probably indirect ones on the host immune system. M-CSF, in combination with LR, 
      may be of benefit in the treatment of human tumors that have metastatic 
      potential.
FAU - Lu, L
AU  - Lu L
AD  - Department of Medicine (Hematology/Oncology), Indiana University School of 
      Medicine, Indianapolis 46202.
FAU - Shen, R N
AU  - Shen RN
FAU - Lin, Z H
AU  - Lin ZH
FAU - Aukerman, S L
AU  - Aukerman SL
FAU - Ralph, P
AU  - Ralph P
FAU - Broxmeyer, H E
AU  - Broxmeyer HE
LA  - eng
GR  - CA 36464/CA/NCI NIH HHS/United States
GR  - CA 36740/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (Recombinant Proteins)
RN  - 81627-83-0 (Macrophage Colony-Stimulating Factor)
SB  - IM
MH  - Animals
MH  - Blood Cells/drug effects/radiation effects
MH  - Bone Marrow/drug effects/radiation effects
MH  - Bone Marrow Cells
MH  - Cell Line
MH  - Combined Modality Therapy
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Lung Neoplasms/*drug therapy/radiotherapy/secondary
MH  - Macrophage Colony-Stimulating Factor/*therapeutic use
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Recombinant Proteins/therapeutic use
MH  - Spleen/cytology/drug effects/radiation effects
MH  - X-Ray Therapy
EDAT- 1991/01/02 00:00
MHDA- 1991/01/02 00:01
CRDT- 1991/01/02 00:00
PHST- 1991/01/02 00:00 [pubmed]
PHST- 1991/01/02 00:01 [medline]
PHST- 1991/01/02 00:00 [entrez]
AID - 10.1002/ijc.2910470125 [doi]
PST - ppublish
SO  - Int J Cancer. 1991 Jan 2;47(1):143-7. doi: 10.1002/ijc.2910470125.